[go: up one dir, main page]

WO2003016344A3 - Use of lung carcinoma antigen - Google Patents

Use of lung carcinoma antigen Download PDF

Info

Publication number
WO2003016344A3
WO2003016344A3 PCT/EP2002/009006 EP0209006W WO03016344A3 WO 2003016344 A3 WO2003016344 A3 WO 2003016344A3 EP 0209006 W EP0209006 W EP 0209006W WO 03016344 A3 WO03016344 A3 WO 03016344A3
Authority
WO
WIPO (PCT)
Prior art keywords
nsclc
lung cancer
carcinoma
lesions
small cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/009006
Other languages
French (fr)
Other versions
WO2003016344A2 (en
Inventor
Swann Romain Jean-Thoma Gaulis
Y De Bassols Carlota Vinals
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Priority to AU2002331231A priority Critical patent/AU2002331231A1/en
Publication of WO2003016344A2 publication Critical patent/WO2003016344A2/en
Publication of WO2003016344A3 publication Critical patent/WO2003016344A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Use of CASB933 polypeptides and polynucleotides in diagnostics, immunogenic compositions and vaccines, for prophylactic and therapeutic treatment of cancers, particularly prenoeplasic lesions of lung cancer, for instance small cell lung cancer (SCLC), or non small cell lung cancer (NSCLC) such as squamous (epidermoid) carcinoma, adenocarcinoma (including bronchoalveolar) and large cell (undifferentiated) carcinoma, or carcinoids, or bronchial gland tumours or mesotheliomas, even more particularly NSCLC preneoplasic lesions and early stage (classification stages 0, or IA, or IB, or IIA, or IIB of Mountains's staging) NSCLC.
PCT/EP2002/009006 2001-08-14 2002-08-12 Use of lung carcinoma antigen Ceased WO2003016344A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002331231A AU2002331231A1 (en) 2001-08-14 2002-08-12 Use of lung carcinoma antigen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0119823A GB0119823D0 (en) 2001-08-14 2001-08-14 Novel compounds
GB0119823.3 2001-08-14

Publications (2)

Publication Number Publication Date
WO2003016344A2 WO2003016344A2 (en) 2003-02-27
WO2003016344A3 true WO2003016344A3 (en) 2003-11-20

Family

ID=9920387

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/009006 Ceased WO2003016344A2 (en) 2001-08-14 2002-08-12 Use of lung carcinoma antigen

Country Status (3)

Country Link
AU (1) AU2002331231A1 (en)
GB (1) GB0119823D0 (en)
WO (1) WO2003016344A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0839908A2 (en) * 1996-10-31 1998-05-06 Smithkline Beecham Corporation A novel human ETS family member, ELF3
WO1998023782A2 (en) * 1996-11-27 1998-06-04 The Regents Of The University Of California A new ets-related gene overexpressed in human breast and epithelial cancers
WO2000055350A1 (en) * 1999-03-12 2000-09-21 Human Genome Sciences, Inc. Human cancer associated gene sequences and polypeptides
WO2000070092A1 (en) * 1999-05-14 2000-11-23 Chiron Corporation Expression of ets-domain proteins in cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0839908A2 (en) * 1996-10-31 1998-05-06 Smithkline Beecham Corporation A novel human ETS family member, ELF3
WO1998023782A2 (en) * 1996-11-27 1998-06-04 The Regents Of The University Of California A new ets-related gene overexpressed in human breast and epithelial cancers
WO2000055350A1 (en) * 1999-03-12 2000-09-21 Human Genome Sciences, Inc. Human cancer associated gene sequences and polypeptides
WO2000070092A1 (en) * 1999-05-14 2000-11-23 Chiron Corporation Expression of ets-domain proteins in cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHANG C-H ET AL: "ESX: a structurally unique Ets overexpressed early during human breast tumorigenesis", ONCOGENE, vol. 14, no. 13, 1997, pages 1617 - 1622, XP000870110, ISSN: 0950-9232 *
TYMMS M J ET AL: "A novel epithelial-expressed ETS gene, ELF3: human and murine cDNA sequences, murine genomic organization, human mapping to 1q32.2 and expression in tissues and cancer", ONCOGENE, vol. 15, no. 20, 13 November 1997 (1997-11-13), pages 2449 - 2462, XP000877469, ISSN: 0950-9232 *

Also Published As

Publication number Publication date
WO2003016344A2 (en) 2003-02-27
GB0119823D0 (en) 2001-10-10
AU2002331231A1 (en) 2003-03-03

Similar Documents

Publication Publication Date Title
EP1272636B8 (en) A gene differentially expressed in breast and bladder cancer and encoded polypeptides
WO2001092581A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2002006317A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
HUP0203968A2 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2002074156A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2003274823A1 (en) Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
AU4673099A (en) Use of bioadhesives and adjuvants for the mucosal delivery of antigens
MXPA06010469A (en) Recombinant protein carrying human papillomavirus epitopes inserted in an adenylate cyclase protein or fragment thereof. therapeutic uses thereof.
WO2004070062A3 (en) Compositions and methods for diagnosing and treating cancers
WO2005016235A3 (en) Combined use of impdh inhibitors with toll-like receptor agonists
NZ524036A (en) Treatment and diagnosis of cancer
NO20026245D0 (en) Enhancement of antibody-cytokine fusion protein-mediated immune responses by combined treatment with immunocytokine uptake agents
PL362670A1 (en) Modified cytokines for use in cancer therapy
WO2003016344A3 (en) Use of lung carcinoma antigen
WO2003026494A3 (en) Galectins-1-and-4 in tumor development
WO2003017944A3 (en) Gpi-anchored cytokines
AU2001249431A1 (en) Compositions and methods of diganosing, monitoring, staging, imaging and treating mammary gland cancer
DE60239690D1 (en) SEPARATED AND CELL SURFACE GENES EXPRESSED IN GOOD AND MASTILE COLOREKTUMUMORS
PL1684801T3 (en) Recombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigens
TW200517122A (en) Antibodies specific for cancer associated antigen SM5-1 and uses thereof
AU2003235791A1 (en) Gene products differentially expressed in cancerous breast cells and their methods of use
WO2002092627A3 (en) Use of casb 7439 for treatment and diagnosis of lung cancer
WO2003030719A3 (en) Methods and kits for use in selecting approaches to treating cancer
WO2002012331A3 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
Pisters Adjuvant and neoadjuvant therapy for early stage non-small cell lung cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP